Transcenta Holding Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Transcenta Holding wird ein Gewinn- und Umsatzwachstum von 0.4% bzw. 16.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 0.5% pro Jahr wachsen soll.

Wichtige Informationen

12.7%

Wachstumsrate der Gewinne

12.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	40.0%
Wachstumsrate der Einnahmen	67.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	03 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

Dec 15

Gewinn- und Umsatzwachstumsprognosen

SEHK:6628 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	339	-265	-86	85	1
12/31/2025	138	-366	-408	-265	2
12/31/2024	132	-421	-1,026	-565	1
6/30/2024	22	-359	-282	-280	N/A
3/31/2024	38	-411	-328	-319	N/A
12/31/2023	54	-463	-374	-358	N/A
9/30/2023	85	-451	-364	-343	N/A
6/30/2023	116	-440	-355	-329	N/A
3/31/2023	109	-424	-336	-312	N/A
12/31/2022	102	-407	-318	-296	N/A
9/30/2022	74	-666	-371	-337	N/A
6/30/2022	45	-925	-424	-377	N/A
3/31/2022	53	-1,748	-467	-419	N/A
12/31/2021	50	-1,716	-440	-384	N/A
9/30/2021	65	-1,457	-377	-321	N/A
6/30/2021	79	-1,199	-314	-258	N/A
3/31/2021	82	-364	-256	-180	N/A
12/31/2020	81	-317	-238	-174	N/A
12/31/2019	44	-395	-457	-235	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 6628 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 6628 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 6628 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 6628Die Einnahmen des Unternehmens (19.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (7.9% pro Jahr).

Hohe Wachstumseinnahmen: 6628Die Einnahmen des Unternehmens (33.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 6628 in 3 Jahren voraussichtlich hoch sein wird

Transcenta Holding Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 36%

Consensus revenue estimates decrease by 17%, EPS upgraded

Recent updates

CEO & Executive Chairman recently bought HK$65k worth of stock

Transcenta Holding Limited Announces the Appointment of Dr. Li Xu as A Non-Executive Director and Member of the Audit Committee

Transcenta Holding Limited to Report First Half, 2024 Results on Aug 28, 2024

CEO & Executive Chairman recently bought HK$67k worth of stock

Transcenta Holding Limited Announces Directorate and Board Changes

Consensus EPS estimates fall by 36%

Transcenta Holding Limited Announces Updates of Phase II Data from First-Line Triple Combination Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024

Transcenta Holding Limited Announces Board and Nomination Changes

New minor risk - Market cap size

Consensus revenue estimates decrease by 17%, EPS upgraded

Transcenta Holding Limited, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥1.14 loss per share (vs CN¥0.94 loss in FY 2022)

Transcenta Holding Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

CEO & Executive Director recently bought HK$74k worth of stock

Transcenta Holding Limited Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging

FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients

New minor risk - Shareholder dilution

First half 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.47 loss in 1H 2022)

Transcenta Holding Limited Announces Management Changes, Effective August 23, 2023

Transcenta Holding Limited to Report First Half, 2023 Results on Aug 22, 2023

Transcenta Holding Limited Receives Approval from China Center for Drug Evaluation to Initiate Phase II Clinical Trial of TST002(Blosozumab)

CEO & Executive Director recently bought HK$50k worth of stock

Transcenta Holding Limited Receives Approval from China CDE and South Korea MFDS to Initiate Transtar301 Global Phase III Pivotal Trial of Osemitamab (TST001)

CEO & Executive Director recently bought HK$70k worth of stock

Transcenta Holding Limited Announces Update on Efficacy Data of Osemitamab Plus Capecitabine and Oxaliplatin

CEO & Executive Director recently bought HK$54k worth of stock

Transcenta Holding Limited Presents Updated Data of Cohort C from Phase I/IIa, Multi-Center Study of Osemitamab

CEO & Executive Director recently bought HK$70k worth of stock

Transcenta Holding Limited Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density

Transcenta Holding Limited to Present Two Clinical Trial Progress At Asco 2023

Transcenta Holding Limited Announces Completion of Enrollment in COHorts C and G of China Phase II Study of Osemitamab (TST001) in Combination with Capecitabine and Oxaliplatin

CEO & Executive Director recently bought HK$72k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Transcenta Holding Limited to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer

Transcenta Receives IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

Transcenta Holding Limited Announces Appointment of Independent Non-Executive Director and Change in the Composition of Board Committees

High number of new and inexperienced directors

CEO & Executive Director recently bought HK$78k worth of stock

Transcenta Holding Limited Provides Update on Prevalence of Claudin18.2 and PD-L1 Expression in Chinese Gastric/Gastroesophageal Junction Adenocarcinoma

Transcenta Holding Limited Receives IND Clearance from FDA for its MASP2 Targeting Antibody TST004 for Treatment of IgA Nephropathy

CEO & Executive Director recently bought HK$72k worth of stock

Transcenta Holding Limited Receives IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

Transcenta Holding Limited Announces that Interim Safety and Efficacy Data of Dose Expansion Cohort from the Phase I/II Study of TST001 (Osemitamab)

Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022

First half 2022 earnings released: CN¥0.47 loss per share (vs CN¥10.19 loss in 1H 2021)

Transcenta Holding Limited to Report First Half, 2022 Results on Aug 29, 2022

Transcenta Holding Limited Announces the Appointment of Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer

Transcenta Holding Limited Announces Change of the Chief Medical Officer

Transcenta Holding Limited Announces Resignation of Michael Ming Shi as Executive Director

Transcenta Holding Limited Announces That It Was Selected to Present the Preclinical Data of Tst004 At the 2022 Isn Frontiers Meetings of Complement-Related Kidney Diseases

Transcenta Holding Limited Announces Demise of Albert Da Zhu, an Executive Director and a Joint Company Secretary

Transcenta Holding Limited Publishes the Results of Preclinical Studies of the Company's First-In-Class Gremlin1 Targeting Antibody in the Treatment of Castration Resistant Prostate Cancer

Less than half of directors are independent

Transcenta Holding Limited Successfully Passes the Audit of EU Qualified Person for the Manufacturing of TST001

CEO & Executive Director recently bought HK$59k worth of stock

Transcenta Holding Limited, Annual General Meeting, Jun 10, 2022

Transcenta Announces First Patient Dosed in Phase IIa Study of Claudin18.2 Monoclonal Antibody TST001 Combined with Cisplatin and Gemcitabine for the First Line Treatment of Biliary Tract Cancer

Transcenta Holding Limited to Present Two Phase I Clinical Trials of Tst001 at Upcoming ASCO GI and IGCC

CEO & Executive Director recently bought HK$864k worth of stock

Transcenta Holding Limited Announces Business Update on the First Patient Dosed in Thephase Ib Clinical Trial of Humanized Anti-Vegfr-2Monoclonal Antibody Msb0254

Transcenta Holding Limited has completed an IPO in the amount of HKD 645.28 million.

Less than half of directors are independent

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken